FDA made a mistake in approving a questionable Alzheimer’s drug, but Medicare could act to reduce false hopes and unethical profits

The government should reimburse Biogen only for actual production costs while further clinical trials determine whether aducanumab really helps patients
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.